REGENXBIO to Participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day
February 02 2017 - 7:00AM
REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company
focused on the development, commercialization and licensing of
recombinant adeno-associated virus (AAV) gene therapy based on its
proprietary NAV® Technology Platform, today announced that it will
participate in the SunTrust Robinson Humphrey 2017 Orphan Drug Day.
The conference will take place on Tuesday, February 14, 2017 at the
JW Marriott Essex House New York in New York, NY. REGENXBIO
representatives will be holding one-on-one meetings at the
conference.
About REGENXBIO
REGENXBIO is a leading biotechnology company focused on the
development, commercialization and licensing of recombinant
adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV®
Technology Platform, a proprietary AAV gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to
transform the lives of patients suffering from severe diseases with
significant unmet medical need by developing and commercializing in
vivo gene therapy products based on REGENXBIO’s NAV Technology
Platform. REGENXBIO seeks to accomplish this mission through a
combination of internal development efforts and third-party NAV
Technology Platform Licensees. REGENXBIO and its licensees are
applying the NAV Technology Platform in the development of a broad
pipeline of candidates in multiple therapeutic areas.
CONTACT:
Investors
Heather Savelle, 646-395-3734
heather@argotpartners.com
Media
Laura Bagby, 312-448-8098
lbagby@6degreespr.com
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Sep 2023 to Sep 2024